Avitide, LLC, a Repligen Company

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals.

See where Flublok® Influenza vaccine is available at www.flublok.com.

We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology:

1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines

2. GeneXpress® product development and manufacturing services - we partner with others to develop and manufacture modern vaccines, therapeutics and gene therapies

3. Research antigens - we offer a variety of high quality purified antigens and antibodies to the scientific community for disease research

RiboWiz Scientific is a digital biotechnology company integrating both A.I. software and life science. RiboWiz offers customized service and cloud-based subscription licensing to accurately predict and maximize recombinant protein production for life science companies using proprietary RiboScan™ software platform.

Creating high-value recombinant proteins, e.g. biologics, enzymes, vaccines, antibodies, and pesticides, is important to life science companies across a broad range of industrial applications. For example, proteins can be over-expressed for use in basic research, used as insecticides, or used as targets for small molecule drugs or antibodies for the treatments of AIDS, diabetes, cancer and other diseases.

Many R&D projects are stymied by conventional protein expression methods that require multiple trial-and-error laboratory testing to produce proteins at the desired level. RiboScan™ provides more of the desired protein candidates with fewer folding errors and protein aggregations by simulating and modulating ribosomal speed and accuracy during protein synthesis.

Unlike current alternatives that require synthesis and laboratory testing of hundreds of genes construct, RiboScan™ accurately predicts protein expression levels and designs an optimized gene construct with minimal subsequent laboratory testing. This significantly accelerates clients’ R&D projects, reduces costs, expedites innovations, and enhances protein quality to make clients more competitive in bringing multiple novel compounds to market faster.

RiboWiz’s mission is to help clients successfully produce high-value, difficult-to-make recombinant proteins faster for new treatments of diseases and also for the advancement of medicine and biotechnology.

Smart Consulting Group provides technical and regulatory compliance support for biotechnology, medical devices, pharmaceuticals, vaccines, and specialty products, solving complex challenges for both the industry and governments.

We provide advisory and support services in a broad range of categories, including but not limited to:

• FDA Regulatory Compliance
• Quality Systems Design and Implementation
• Forensic Analysis for Data Integrity
• GMP, GLP, and GCP Audits
• Assessments and benchmarking
• Compliance and Quality Risk Assessment
• Regulatory Strategy
• Product/Process Development/Manufacturing
• Laboratory Compliance and Operations Analysis
• Documentation Management Support
• Project Management
• Technology Transfer Strategy and Oversight
• Staffing support for highly specialized talent
• Support services to facilitate organizational change

Smart Consulting Group has expertise in solid dosage forms, parenteral pharmaceuticals, a wide range of biological products, vaccines, recombinant products, monoclonal antibodies, cell therapies, tissue-engineered products, and device-combo products.

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc., Akston’s COVID-19 vaccine candidate is in Phase II trials in the Netherlands. It has partnered with Dechra Pharmaceuticals PLC to commercialize once-a-week canine and feline insulin therapies. The company employs 35 people, has over 3,500 ft2 of research laboratory space and a 12,400 ft2 GMP clean room biologics manufacturing facility.

Follow us for the latest on our expansion, job opportunities and the latest relevant news in our space!

Biodextris is comprised of experienced product development scientist located in Laval (Montreal), Quebec. The group has worked together since 2002, as part of ID Biomedical and later GSK-Vaccines. We have developed numerous products for all phases of clinical development for programs conducted in the US, Canada and Europe.

Companies choose to work with us because we are experts in developing complete analytical packages for novel and complex products. Companies trust us to accelerate their project from the bench to the clinic by delivering robust and reliable production processes ready for manufacturing. Companies rely on our Quality Control testing services for their clinical phase vaccines and biologics.

We look forward to sharing this expertise with you.